ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD)
August 7th, 2018
ACADIA Pharmaceuticals Inc. rose $0.23 Sunday, up 1.65%, closing at $14.14. With an estimated two days to the next earnings report, everyone is watching ACADIA Pharmaceuticals Inc.. While it is positive news the stock ended higher, the trading volumes were only 34% of normal which could be an indication of investor uncertainty.
ACAD outperformed the rest of the Healthcare sector which went up 0.07% today.
ACADIA Pharmaceuticals Inc. Info
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.